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ISSNObjective: We investigated the association between immune response and mortality in
four HIV African programs supported by Me´decins Sans Frontie`res.
Design: Multicentric retrospective cohort study.
Methods: All antiretroviral therapy (ART) naive adults (>15 years) who initiated
therapy between March 2001 and November 2010 and receiving therapy for 9 months
or more were included. We described the evolution of mortality over time. Mixed
Poisson models were used to assess the effect of updated CD4 cell counts and other
potential risk factors on mortality.
Findings: A total of 24 037 patients, of which 68% were women, contributed 69 516.2
person-years of follow-up. At ART initiation, 5718 patients (23.7%) were classified as
WHO clinical stage 4, 1587 (6.6%) had a BMI below 16 kg/m2 and 2568 (10.7%) had
CD4 cell count below 50 cells/ml. A total of 568 (2.4%) deaths were recorded during the
study period. In the CD4 response categories 500 cells/ml or more, 350–499, 200–349,
50–199 cells/ml and less than 50 cells/ml, unadjusted mortality rates were 0.36; 0.58;
0.88; 1.91 and 7.43 per 100 person-years, respectively. In multivariate analysis, higher
mortality was observed in patients with CD4 response levels 350–499 cells/ml [adjusted
hazard ratio (aHR) 1.70, 95% confidence interval (CI) 1.26–2.30] and for those
between 200–349 (aHR 2.56; 95% CI 1.93–3.38), compared to those with
500 cells/ml or more.
Interpretation: The observed higher survival of patients with a CD4 response to ART
higher than 500 cells/ml supports the need of further research to evaluate the individual
benefit of initiating ART at higher CD4 levels in sub-Saharan Africa.
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By the end of 2009, almost 4 million patients were
receiving antiretroviral therapy (ART) in sub-Saharan
Africa [1]. Many national ART scaling-up programs in
sub-Saharan African began in 2004 or 2005 and there are
increasing numbers of patients that have medium or long-
term experience with ART. Reports from evaluations of
long-term mortality are relatively scarce and few studies
have investigated risk factors associated with longer term
mortality. In Senegal, mortality decreased from 12.5 per
100 person-years during the first year to 2.2 per 100
person-years during the fifth year on ART [2]. In
Botswana, survival estimates at 1 and 5 years of ART
reported little difference, 0.82 and 0.79, respectively [3].
Additionally, a recent South African study reported a
corrected mortality estimate of 20.9% after 5 years of
treatment [4].
In resource-limited settings, the optimal CD4 cell count
level to initiate ART is still debated. Current WHO
guidelines recommend starting ART when CD4 cell
count levels reach 350 cells/ml, whereas US national
guidelines have raised this threshold to 500 [5,6]. As
clinical trials studying the potential individual benefits of
starting ART earlier are still years from completion,
observational studies exploring the relation between CD4
response to ART and mortality could help by providing
indirect evidence.
This analysis aimed at describing mortality among HIV-
infected patients receiving ART for 9 months or more
and studying its association with CD4 response and other
risk factors in four large sub-Saharan African programs
supported by Me´decins Sans Frontie`res.Methods
Data collection
We used data from four HIV programs (Malawi, Uganda
and two programs in Kenya) where ART became
available between 2001 and 2002. All care and treatment,
including antiretroviral drugs, were provided free of
charge.
Routine demographic, clinical, biological and treatment
data (including ART regimens) were recorded using a
standardized monitoring system (FUCHIA software,
Epicentre, Paris, France).
Deaths were recorded by the medical teams, reported by a
close relative or friend, or from 2006, by a member of the
tracing team after house visits.
CD4 cell counts were initially quantified using manual
methods (Dynabeads; Dynal Biotech SA, Compie`gne,pyright © Lippincott Williams & Wilkins. UnauthoFrance) and, since 2003, with semiautomated techniques
(Cyflow counter; Partec, Munster, Germany or FACS-
count; Becton-Dickinson Immunocytometry Systems,
San Jose, California, USA). During treatment, CD4 cell
counts were routinely monitored every 6–12 months.
The study protocol was approved by the ‘Comite´ de
protection des personnes d’Ile de France’, Paris, France.
Inclusion criteria
All HIV-infected patients who, at ART start, were aged
15 years or older, had no history of ART use, had been
receiving therapy for more than 9 months and had at least
one CD4 measure after 9 months on ART, were included
in the analysis.
Statistical analysis
Study follow-up started 9 months after ART initiation.
Censoring occurred at death, loss to follow-up or at the
last consultation, whatever came first. The database was
locked on 30 November 2010.
Loss to follow-up was defined as the absence of recorded
clinical visit for at least 9 months at the time of the analysis
among patients who were not dead or transferred out of
the program.
Two types of CD4measures were included in the analysis:
initial (closest measurement between three months before
and one month after ART start) and updated CD4 cell
counts (all tests performed after 9 months of ART). Initial
CD4 cell counts were less than 50, 50–199, 200 cells/ml
or more and missing. Updated CD4 cell counts were
grouped into five categories: less than 50, 50–199, 200–
349, 350–499 and 500 cells/ml or more. BMI and WHO
clinical stage at ART initiation were also considered for
the analysis as categorical variables.
We estimated the mortality rates per 100 person-years
with 95% confidence interval (CI) from 9 months after
ART initiation and up to 5 years of therapy use.
We then explored factors associated with mortality after
the first 9 months of ART. A mixed Poisson survival
model was used to explore the association between
mortality and CD4 response measured after 9 months of
ART. Time at risk started from the date of blood sample
collection of the first CD4 measure taken after 9 months
on ARTuntil death, end of follow-up or the next CD4
cell count measure, whatever came first. The model was
adjusted for program, sex and characteristics measured at
ART start (age, BMI, CD4 cell count level and clinical
WHO stage), all included as categorical variables. Missing
initial values of BMI, clinical stage, and CD4 cell counts
were included as separate categories in the analysis.
Data were analysed using Stata 11 (Stata Corp, College
Station, Texas, USA).rized reproduction of this article is prohibited.
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Study population characteristics
A total of 24 037 patients met the inclusion criteria and
contributed 69 516.2 person-years of follow-up (Fig. 1).
Women represented 68% of the study population. At
ART initiation, 5718 patients (23.8%) were in WHO
clinical stage 4 and 1587 (7%) had a BMI below 16 kg/m2.
The median CD4 cell count was 152 cells/ml [inter-
quartile range (IQR) 84–211] and 2568 patients (11%)
had a CD4 cell count below 50 cells/ml (Table 1). During
the study follow-up, 568 (2.4%) patients died and 2796
(10.3%) were lost to follow-up.Median time of follow-up
in the programs after ART start was 3.33 years (IQR
2.10–5.00).
Mortality rates
Overall mortality rate was 0.82 deaths per 100 person-
years (95%CI 0.75–0.88). Mortality rates were 1.03 (95%
CI 0.91–1.18), 0.93 (95% CI 0.79–1.09) and 0.64
(95% CI 0.48–0.86) deaths/100 person-years, during
the second, third and fourth years of ART, respectively.Associations between mortality and CD4
response
Overall, 77 970 CD4 measures were available for the
analysis. The median number of measures per patient was




27018 patients receiving ART for more
than 9 months
24 037 patients
Fig. 1. Patient study flow chart, Kenya, Uganda and Malawi, 200Unadjusted mortality rates were 0.36 (95% CI 0.29–
0.44), 0.58 (95% CI 0.48–0.71), 0.88 (95% CI
0.75–1.01), 1.91 (95% CI 1.65–2.22) and 7.43 (95% CI
5.43–10.2) in the CD4 response strata at least 500, 350–
499, 200–349, 50–199 cells/ml and less than 50 cells/ml.
In the multivariate analysis, mortality decreased with
increasing CD4 cell count levels during treatment
(likelihood ratio test for trend P< 0.001; Table 1).
Patients with CD4 cell counts greater than 500 cells/ml
had better survival than those with levels between 350 and
500 cells/ml [adjusted hazard ratio (aHR) 1.70; 95% CI
1.26–2.30] and with CD4 cell counts between 200 and
349 cells/ml (aHR 2.56; 95% CI 1.93–3.38).
Initial BMI and clinical stage were associated with
mortality. Mortality among patients in clinical stage 4 was
1.99 times higher than among those in stage 1 (95% CI
1.22–3.23). Patients with initial BMI below 16 kg/m2
had higher mortality than those with BMI over than
18 kg/m2 (aHR 1.61; 95% CI 1.17–2.21). Overall
women experienced better survival than men (aHR 1.33;
95% CI 1.10–1.61).Discussion
We studied the association between mortality and
CD4 response following the first 9 months of ART usehorized reproduction of this article is prohibited.
- Unknown age: 269
- Children: 4079
- Initial history of ART: 3552
10 531 patients receiving ART for
less than 9 months
2981 patients with no CD4 values
after 9 months of ARTuse
1–2010. ART, antiretroviral therapy.
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Table 1. Association between patient characteristics at antiretroviral therapy start and updated CD4 cell count levels, and death after 9 months
of antiretroviral therapy initiation.
Number of patients (%) Number of deaths Number of person, years Adjusted HR (95% CI)
N¼24 037 N¼568 N¼69 516.2
HIV program
Kenya 1 3883 (16.2) 107 14 508.0 1
Kenya 2 2136 (8.9) 67 6132.4 1.74 (1.23–2.47)
Malawi 13 046 (54.3) 298 34 124.3 1.61 (1.25–2.10)
Uganda 4972 (20.7) 96 14 751.8 1.62 (1.25–2.10)
Sex
Female 16 355 (68.0) 322 48 155.5 1
Male 7682 (32.0) 246 21 360.9 1.33 (1.10–1.61)
Agea (years)
15–30 6254 (26.0) 113 17 609.2 1
30–50 15 356 (63.9) 354 45 407.8 1.11 (0.88–1.41)
>50 2427 (10.1) 101 6499.5 2.42 (1.77–3.31)
Clinical stagea
1 3571 (14.9) 23 6140.5 1
2 4471 (18.6) 72 11 279.1 1.39 (0.85–2.29)
3 9200 (38.3) 205 29 960.2 1.24 (0.77–1.98)
4 5718 (23.8) 243 19 313.2 1.99 (1.22–3.23)
Unknown 1077 (4.5) 25 2823.5 1.75 (0.95–3.22)
BMIa (kg/m2)
18 18 113 (75.4) 349 51 883.0 1
17 and <18 2546 (10.6) 78 7514.3 1.36 (1.03–1.80)
16 and <17 1628 (6.8) 64 4894.3 1.60 (1.17–2.18)
<16 1587 (6.6) 64 4881.1 1.61 (1.17–2.21)
Unknown 163 (0.7) 13 343.8 5.56 (2.77–11.17)
Initial CD4 cell counta (cells/ml)
200 5543 (23.1) 66 12 026.0 1
50–199 10 710 (44.6) 217 31 411.9 0.79 (0.58–1.08)
<50 2568 (10.7) 76 8060.7 0.63 (0.43–0.92)
Unknown 5216 (21.7) 209 18 017.8 1.07 (0.77–1.48)
Updated CD4 cell count (cells/ml)
>500 26 891 (34.5) 81 22 719.9 1
350–499 19 285 (24.7) 103 17 632.2 1.70 (1.26–2.30)
200–349 20 752 (26.6) 171 19 527.4 2.56 (1.93–3.38)
50–199 10 250 (13.2) 174 9112.6 5.74 (4.30–7.68)
<50 792 (1.0) 39 524.3 25.76 (16.0–41.3)
Period of ART start
2008–2010 7371 (30.7) 27 8104.7 1
2006–2007 7916 (32.9) 160 21 110.7 2.39 (1.56–3.67)
2004–2005 6300 (26.2) 241 26 902.3 2.93 (1.89–4.54)
2001–2003 2450 (10.2) 140 13 398.5 3.77 (2.37–5.96)
Mixed Poisson model, Uganda, Malawi and Kenya, 2001–2010; 77 970 CD4 values. ART, antiretroviral therapy.
aInformation measured at ART initiation.in four large HIV programs in sub-Saharan Africa. We
found a significant negative dose-response relationship
between on-treatment CD4 and mortality. The lowest
mortality estimates were observed among patients who
had reached on-treatment CD4 levels higher than
500 cells/ml.
This cohort study demonstrates on-treatment mortality
decreases when patients reach 500 CD4 cells per
microlitre compared to 350–500 cells/ml. This analysis
reinforces the findings of two recent cohort studies that
have showed a higher incidence of tuberculosis and
Kaposi sarcoma, two frequent opportunistic infections,
among patients with on-treatment CD4 cell counts
ranging from 350 to 500 cells/ml compared to those
reaching higher CD4 cell count [7,8]. Another recent
study reported similar association between levels of CD4
cell counts and mortality among pre-ART patientspyright © Lippincott Williams & Wilkins. Unauthotreated in Europe and north America [9]. Despite the
long time frame and the difference in patient character-
istics (pre-ART patients and the majority of deaths
happened to intravenous drug users), this study provided
the first evidence that pre-ART patients with a CD4 cell
count falling below 500 cells/ml experienced higher
mortality than patients maintaining their CD4 cell count
above this level. So far, two observational studies from
developed countries found a higher incidence of AIDS-
related events for patients initiating ART between 350
and 500 cell/ml compared to those initiating over
500 cell/ml, but found no effect on mortality [10,11].
However, we could hypothesize outcomes to be different
in sub-Saharan Africa where capacities to accurately
diagnose and treat opportunistic infections are more
limited. Therefore, further studies to evaluate the impact
of starting patients at higher CD4 cell counts are required
in sub-Saharan Africa.rized reproduction of this article is prohibited.
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of follow-up and the large number of patients included
and coming from some of the first HIV programs that
provided ART at large scale in sub-Saharan Africa.
A further strength was that programs included use of
a similar standardized routine monitoring system.
Concerning statistical analysis, residual individual
heterogeneity due to repeated CD4 measures in same
individuals was accounted for using mixed survival
models. Furthermore, the multivariate analyses allowed
adjusting for the effect of covariates including sex,
patient characteristics at ART start, program and
adherence.
We possibly underestimated mortality as 10.3% of patients
were lost to follow-up during the study period. Results of
the sensitivity analyses in which all the patients lost to
follow-up were considered as dead weakened all the
incidence rate ratios. However, it did not affect the
conclusions of the primary analysis; patients with a CD4
response of at least 500 cells/ml still had better survival
than those with 350/500 (e-content).
Including missing initial CD4 cell counts in the analysis as
a category, and to a lesser extent missing clinical stage and
BMI may have contributed to bias our results. We chose
this strategy because missing information was not at
random and represented patients with very advanced
clinical disease. Our first model showed that patients
with missing initial CD4 cell count had similar mortality
than those severely immunosuppressed. In the sensitivity
analysis restricted to patients with complete data
(e-content), the conclusions of the main analyses did
not change.
We assumed that CD4 cell counts remained constant
between two consecutive measures or until the end of
follow-up for the last measurement. Given that CD4 cell
counts taken were those measured after 9 months of
therapy when the slope of immune reconstitution is
flatter, potential-related lead-time bias would have been
minimized. CD4 cell count is a measure of immunity,
which has a strong physiological variability [12]. This
variability seems to lead to nondifferential misclassifi-
cation resulting in underestimation of the magnitude of
the CD4 response effect on survival [13].
The generalizability of our findings is reinforced by the
inclusion of program data from four different sub-Saharan
African cohorts, one in an urban area and three located in
rural ones. All the sites are located in countries with high
HIV prevalence. However, as our analysis used data from
programs supported byMe´decins Sans Frontie`res wherein
additional human and diagnostic resources are generally
available, we could hypothesize that in sub-Saharan
African programs, not receiving this extra support, the
survival benefit achieved by reaching 500 CD4 cell counts
would be even higher.Copyright © Lippincott Williams & Wilkins. UnautOur study highlights the need to further evaluate the
impact of starting patients at higherCD4 cell counts in sub-
Saharan Africa for their own individual benefits. A
consequent decrease in mortality and morbidity would
contribute to the simplification of monitoring procedures.Acknowledgements
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